Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover low deposit secured credit cards that help you build credit with a small upfront investment and manageable terms.
13,475 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Insider buying can hint at confidence from leadership, but it isn’t a crystal ball. This guide explains how to interp...
A high-earning couple weighs a public-service run with a $34,000 pay cut, but Ramsey-trained finance logic says the r...
Three dividend aristocrats have boosted payouts for a combined 187 years, delivering steady passive income for invest...
Exxon Mobil topped expectations in Q1 as LNG and Guyana projects accelerate. Investors are eyeing exxon mobil’s next ...
AST SpaceMobile has been a wild ride for investors. This guide explains why spacemobile impossible ignore right is a ...
Shopify delivered strong quarterly results, but the stock traded lower as guidance softened. This article explains wh...
Gusto, the San Francisco-based HR software maker, posts more than $1 billion in trailing revenue for the last 12 mont...
Snap faces another disappointing quarter as ad revenue slows and user growth stalls. With mounting headwinds, many an...
A major fund reportedly dumped million in Netskope stock after the cloud-security name sank about half from its IPO l...
Two popular ETFs both target consumer staples, but their weighting methods lead to distinct risk and return profiles....
Amazon's liquidity position is tightening as it pours billions into AI infrastructure. Investors pore over cash metri...